Edwards Lifesciences (EW) is an American medical equipment company specializing in artificial heart valves and hemodynamic monitoring. It is mostly known for a transcatheter aortic heart valve made of bovine tissue within a collapsible stainless-steel stent, deployed via catheter. Their SAPIEN product is an FDA-approved device for percutaneous aortic valve replacement. It is publicly traded on the NYSE under the symbol EW.
Edwards Lifesciences Corp (EW) Stock Price Up 19.5% Following Analyst Upgrade Edwards Lifesciences Corp (NYSE:EW) was up 19.5% during trading on Monday after Canaccord Genuity raised their price target on the stock from $95.00 to $113.00, Market Beat Ratings reports. Canaccord Genuity currently has a buy rating on the stock. Edwards Lifesciences Corp traded as high as $107.90 and last traded at $107.44, with a volume of 6,338,522 shares traded. The stock had previously closed at $89.92. Other equities analysts have also recently issued reports about the stock. BTIG Research reaffirmed a “neutral” rating on shares of Edwards Lifesciences Corp in a report on Wednesday, December 9th. Cowen and Company lowered their price objective on shares of Edwards Lifesciences Corp from $92.50 to $46.50 and set an “outperform” rating on the stock in a research report on Thursday, December 10th. Stifel Nicolaus increased their target price on shares of Edwards Lifesciences Corp from $89.50 to $97.50 and gave the stock a “buy” rating in a research note on Thursday, December 10th. Jefferies Group raised their price target on Edwards Lifesciences Corp from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, December 17th. Finally, Credit Suisse restated an “outperform” rating and issued a $88.00 price target (up previously from $81.00) on shares of Edwards Lifesciences Corp in a research report on Wednesday, December 23rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and nineteen have given a buy rating to the company’s stock. Edwards Lifesciences Corp has a consensus rating of “Buy” and a consensus target price of $91.70. In other news, CEO Michael A. Mussallem sold 59,000 shares of the business’s stock in a transaction on Thursday, March 17th. The shares were sold at an average price of $84.39, for a total transaction of $4,979,010.00. Following the transaction, the chief executive officer now directly owns 80,650 shares of the company’s stock, valued at $6,806,053.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Patrick B. Verguet sold 8,000 shares of the company’s stock in a transaction on Thursday, January 21st. The shares were sold at an average price of $77.00, for a total transaction of $616,000.00. Following the completion of the transaction, the vice president now owns 99,803 shares of the company’s stock, valued at $7,684,831. The disclosure for this sale can be found here. A number of institutional investors have recently modified their holdings of the company. Bright Rock Capital Management LLC raised its position in shares of Edwards Lifesciences Corp by 100.0% in the fourth quarter. Bright Rock Capital Management LLC now owns 14,000 shares of the medical research company’s stock worth $1,106,000 after buying an additional 7,000 shares in the last quarter. Watch Point Trust Company acquired a new stake in shares of Edwards Lifesciences Corp during the fourth quarter worth about $1,551,000. American Century Companies Inc. acquired a new stake in shares of Edwards Lifesciences Corp during the fourth quarter worth about $59,747,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Edwards Lifesciences Corp by 406.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 152,361 shares of the medical research company’s stock worth $12,033,000 after buying an additional 122,250 shares during the last quarter. Finally, Bremer Trust National Association raised its stake in shares of Edwards Lifesciences Corp by 99.2% in the fourth quarter. Bremer Trust National Association now owns 4,744 shares of the medical research company’s stock worth $374,000 after buying an additional 2,362 shares during the last quarter. The stock has a 50 day moving average price of $86.80 and a 200 day moving average price of $79.47. The firm has a market cap of $22.99 billion and a price-to-earnings ratio of 47.62. Edwards Lifesciences Corp (NYSE:EW) last released its quarterly earnings data on Tuesday, February 2nd. The medical research company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. The company had revenue of $671.10 million for the quarter, compared to analyst estimates of $647.44 million. The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.06 earnings per share. On average, equities research analysts predict that Edwards Lifesciences Corp will post $2.64 EPS for the current year. Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve.
Reported after close today (4/26/16) Earnings: EPS $0.71 Revenue $697M Estimates: EPS $0.66 Revenue $665M
Reported after close today (7/26/16) Earnings: EPS $0.76 Revenue $759.3M Estimates: EPS $0.70 Revenue $724.26M Up 6.41% after hours
Reported after close today (10/25/16) Earnings: EPS $0.68 Revenue $739.4M Estimates: EPS $0.68 Revenue $749.14M Down 13.14% after hours
Analyst Upgrade/Downgrade Update Brokerage firm: Stifel Change: Coverage Reiterated/Price Target Changed Previous Rating: N/A Current Rating: Buy Previous Price Target: $122 Current Price Target: $114 Analyst Upgrade/Downgrade Update Brokerage firm: RBC Capital Mkts Change: Coverage Reiterated/Price Target Changed Previous Rating: N/A Current Rating: Outperform Previous Price Target: $130 Current Price Target: $123
Poor close today by EW. The range 100.90 - 106.70 has been gapped over twice in the last year, will it go for a fill?
Personally from the looks of it I'd try for a bounce off $108-$110 first for roughly a 10% gain. Tight stop though because the risk/reward's not great if you let it ride down to close that gap you spoke of.
Went down to 107.35 last week but quickly got back up to close that day at 109.37. However today's action is poor...it's down at 108.25. Is this going to get hit by the stock rotation too?
